Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

A Comprehensive Review on the State of the Art of Breast Cancers in Italy

Author(s): Domenico Iacopetta, Jessica Ceramella, Alessia Catalano*, Camillo Rosano, Annaluisa Mariconda, Federica Giuzio, Daniela Bonofiglio, Carmela Saturnino, Pasquale Longo and Maria Stefania Sinicropi

Volume 31, Issue 18, 2024

Published on: 11 January, 2024

Page: [2486 - 2506] Pages: 21

DOI: 10.2174/0109298673283289231214095230

Price: $65

Abstract

Breast cancer (BC) currently represents one of the most prevalent cancers among women worldwide and the leading cause of cancer death among women, also negatively affecting the quality of life (QoL) in patients. Over the past two decades, BC research has led to extraordinary advances in our understanding of the disease, resulting in more effective treatments. However, its occurrence is still increasing. Several new treatments are now under development worldwide, but they are not devoid of wellknown side effects, and a great number of patients develop endocrine resistance. Nevertheless, the design and synthesis of more suitable strategies and new drugs to treat breast cancers, overcome resistance and side effects, and obtain better therapeutic outcomes are needed. In this review, we summarize the therapies and the clinical studies currently ongoing in Italy for the treatment of BCs, mainly HER2+ MBC, HER2-low MBC, and TNBC, focusing on the most recent ones, also in consideration of diverse facets, including some aspects related to QoL. Finally, some studies related to the usefulness of physical activity in BC will be cited.

Keywords: Breast cancer, HER2+ MBC, TNBC, HER2-low BCs, QoL, physical activity.

[1]
Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin., 2023, 73(1), 17-48.
[http://dx.doi.org/10.3322/caac.21763] [PMID: 36633525]
[2]
Iacopetta, D.; Ceramella, J.; Baldino, N.; Sinicropi, M.; Catalano, A. Targeting breast cancer: An overlook on current strategies. Int. J. Mol. Sci., 2023, 24(4), 3643.
[http://dx.doi.org/10.3390/ijms24043643] [PMID: 36835056]
[3]
Tarantino, P.; Viale, G.; Press, M.F.; Hu, X.; Penault-Llorca, F.; Bardia, A.; Batistatou, A.; Burstein, H.J.; Carey, L.A.; Cortes, J.; Denkert, C.; Diéras, V.; Jacot, W.; Koutras, A.K.; Lebeau, A.; Loibl, S.; Modi, S.; Mosele, M.F.; Provenzano, E.; Pruneri, G.; Reis-Filho, J.S.; Rojo, F.; Salgado, R.; Schmid, P.; Schnitt, S.J.; Tolaney, S.M.; Trapani, D.; Vincent-Salomon, A.; Wolff, A.C.; Pentheroudakis, G.; André, F.; Curigliano, G. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann. Oncol., 2023, 34(8), 645-659.
[http://dx.doi.org/10.1016/j.annonc.2023.05.008] [PMID: 37269905]
[4]
Agostinetto, E.; Rediti, M.; Fimereli, D.; Debien, V.; Piccart, M.; Aftimos, P.; Sotiriou, C.; de Azambuja, E. HER2-low breast cancer: Molecular characteristics and prognosis. Cancers, 2021, 13(11), 2824.
[http://dx.doi.org/10.3390/cancers13112824] [PMID: 34198891]
[5]
Zhang, H.; Peng, Y. Current biological, pathological and clinical landscape of HER2-low breast cancer. Cancers, 2022, 15(1), 126.
[http://dx.doi.org/10.3390/cancers15010126] [PMID: 36612123]
[6]
D’Arienzo, A.; Verrazzo, A.; Pagliuca, M.; Napolitano, F.; Parola, S.; Viggiani, M.; Caputo, R.; Puglisi, F.; Giuliano, M.; Del Mastro, L.; Arpino, G.; De Laurentiis, M.; Montemurro, F. Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations. EClinicalMedicine, 2023, 62, 102113.
[http://dx.doi.org/10.1016/j.eclinm.2023.102113] [PMID: 37554126]
[7]
Shyam Sunder, S.; Sharma, U.C.; Pokharel, S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management. Signal Transduct. Target. Ther., 2023, 8(1), 262.
[http://dx.doi.org/10.1038/s41392-023-01469-6] [PMID: 37414756]
[8]
Tarantino, P.; Corti, C.; Schmid, P.; Cortes, J.; Mittendorf, E.A.; Rugo, H.; Tolaney, S.M.; Bianchini, G.; Andrè, F.; Curigliano, G. Immunotherapy for early triple negative breast cancer: Research agenda for the next decade. NPJ Breast Cancer, 2022, 8(1), 23.
[http://dx.doi.org/10.1038/s41523-022-00386-1] [PMID: 35181659]
[9]
Heins, M.J.; de Ligt, K.M.; Verloop, J.; Siesling, S.; Korevaar, J.C.; Berendsen, A.; Brandenbarg, D.; Dassen, A.; Jager, A.; Hugtenburg, J.; Weele, G. Adverse health effects after breast cancer up to 14 years after diagnosis. Breast, 2022, 61, 22-28.
[http://dx.doi.org/10.1016/j.breast.2021.12.001] [PMID: 34891036]
[10]
Boszkiewicz, K.; Piwowar, A.; Petryszyn, P. Aromatase inhibitors and risk of metabolic and cardiovascular adverse effects in breast cancer patients - A systematic review and meta-analysis. J. Clin. Med., 2022, 11(11), 3133.
[http://dx.doi.org/10.3390/jcm11113133] [PMID: 35683517]
[11]
Lemij, A.A.; de Glas, N.A.; Derks, M.G.M.; Bastiaannet, E.; Merkus, J.W.S.; Lans, T.E.; van der Pol, C.C.; van Dalen, T.; Vulink, A.J.E.; van Gerven, L.; Guicherit, O.R.; Linthorst-Niers, E.M.H.; van den Bos, F.; Kroep, J.R.; Liefers, G.J.; Portielje, J.E.A. Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer. Breast Cancer Res. Treat., 2022, 193(3), 567-577.
[http://dx.doi.org/10.1007/s10549-022-06583-7] [PMID: 35441273]
[12]
Keane, D.; Phillips, G.; Mitchell, N.; Connolly, R.M.; Hegarty, J. Improving quality of life and symptom experience in patients with metastatic breast cancer: A systematic review of supportive care interventions. Psychooncology, 2023, 32(8), 1192-1207.
[http://dx.doi.org/10.1002/pon.6183] [PMID: 37434307]
[13]
Sun, H.; Xu, J.; Dai, S.; Ma, Y.; Sun, T. Breast cancer brain metastasis: Current evidence and future directions. Cancer Med., 2023, 12(2), 1007-1024.
[http://dx.doi.org/10.1002/cam4.5021] [PMID: 35822637]
[14]
Farahani, M.K.; Gharibshahian, M.; Rezvani, A.; Vaez, A. Breast cancer brain metastasis: From etiology to state-of-the-art modeling. J. Biol. Eng., 2023, 17(1), 41.
[http://dx.doi.org/10.1186/s13036-023-00352-w] [PMID: 37386445]
[15]
Vega Cano, K.S.; Marmolejo Castañeda, D.H.; Escrivá-de-Romaní, S.; Saura, C. Systemic therapy for HER2-positive metastatic breast cancer: Current and future trends. Cancers, 2022, 15(1), 51.
[http://dx.doi.org/10.3390/cancers15010051] [PMID: 36612047]
[16]
Simion, L.; Augustin, I.G.; Volovat, S.R.; Froicu, E.M.; Schenker, M.; Mazilu, L.; Nitipir, C.; Zivari, M.; Volovat, C.; Alecu, M.; Tanase, B.; Cirimbei, C.; Luca, D.C.; Stanculeanu, D.L.; Zob, D.L. HER2 positive breast cancer therapy - A challenging and continuously moving pathway – A narrative literature review. Arch Breast Cancer., 2022, 10(1), 15-25.
[http://dx.doi.org/10.32768/abc.202310115-25]
[17]
von Arx, C.; De Placido, P.; Caltavituro, A.; Di Rienzo, R.; Buonaiuto, R.; De Laurentiis, M.; Arpino, G.; Puglisi, F.; Giuliano, M.; Del Mastro, L. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. Cancer Treat. Rev., 2023, 113, 102500.
[http://dx.doi.org/10.1016/j.ctrv.2022.102500] [PMID: 36587473]
[18]
Gion, M.; Trapani, D.; Cortés, A.; Valenza, C.; Lin, N.; Cortés, J.; Curigliano, G. Systemic therapy for HER2-positive metastatic breast cancer: Moving into a new era. Am. Soc. Clin. Oncol. Educ. Book, 2022, 42(42), 82-92.
[http://dx.doi.org/10.1200/EDBK_351222] [PMID: 35671434]
[19]
Agostinetto, E.; Montemurro, F.; Puglisi, F.; Criscitiello, C.; Bianchini, G.; Del Mastro, L.; Introna, M.; Tondini, C.; Santoro, A.; Zambelli, A. Immunotherapy for HER2-positive breast cancer: Clinical evidence and future perspectives. Cancers, 2022, 14(9), 2136.
[http://dx.doi.org/10.3390/cancers14092136] [PMID: 35565264]
[20]
Hudis, C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med., 2007, 357(1), 39-51.
[http://dx.doi.org/10.1056/NEJMra043186] [PMID: 17611206]
[21]
Guidance for industry: pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. Food and Drug Administration, 2014, Available from: https://www.fda.gov/downloads/drugs/guidances/ucm305501.pdf
[22]
Howie, L.J.; Scher, N.S.; Amiri-Kordestani, L.; Zhang, L.; King-Kallimanis, B.L.; Choudhry, Y.; Schroeder, J.; Goldberg, K.B.; Kluetz, P.G.; Ibrahim, A.; Sridhara, R.; Blumenthal, G.M.; Pazdur, R.; Beaver, J.A. FDA approval summary: Pertuzumab for adjuvant treatment of HER2-positive early breast cancer. Clin. Cancer Res., 2019, 25(10), 2949-2955.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-3003] [PMID: 30552112]
[23]
Krop, I.E.; Kim, S.B.; Martin, A.G.; LoRusso, P.M.; Ferrero, J.M.; Badovinac-Crnjevic, T.; Hoersch, S.; Smitt, M.; Wildiers, H. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol., 2017, 18(6), 743-754.
[http://dx.doi.org/10.1016/S1470-2045(17)30313-3] [PMID: 28526538]
[24]
Baselga, J.; Lewis Phillips, G.D.; Verma, S.; Ro, J.; Huober, J.; Guardino, A.E.; Samant, M.K.; Olsen, S.; de Haas, S.L.; Pegram, M.D. Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin. Cancer Res., 2016, 22(15), 3755-3763.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-2499] [PMID: 26920887]
[25]
Diéras, V.; Miles, D.; Verma, S.; Pegram, M.; Welslau, M.; Baselga, J.; Krop, I.E.; Blackwell, K.; Hoersch, S.; Xu, J.; Green, M.; Gianni, L. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): A descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol., 2017, 18(6), 732-742.
[http://dx.doi.org/10.1016/S1470-2045(17)30312-1] [PMID: 28526536]
[26]
Cortés, J.; Kim, S.B.; Chung, W.P.; Im, S.A.; Park, Y.H.; Hegg, R.; Kim, M.H.; Tseng, L.M.; Petry, V.; Chung, C.F.; Iwata, H.; Hamilton, E.; Curigliano, G.; Xu, B.; Huang, C.S.; Kim, J.H.; Chiu, J.W.Y.; Pedrini, J.L.; Lee, C.; Liu, Y.; Cathcart, J.; Bako, E.; Verma, S.; Hurvitz, S.A. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med., 2022, 386(12), 1143-1154.
[http://dx.doi.org/10.1056/NEJMoa2115022] [PMID: 35320644]
[27]
Hurvitz, S.A.; Hegg, R.; Chung, W-P.; Im, S.A.; Jacot, W.; Ganju, V. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet, 2022, 401, 105-117.
[28]
Perez, E.A.; Barrios, C.; Eiermann, W.; Toi, M.; Im, Y.H.; Conte, P.; Martin, M.; Pienkowski, T.; Pivot, X.B.; Burris, H.A., III; Petersen, J.A.; De Haas, S.; Hoersch, S.; Patre, M.; Ellis, P.A. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE. Cancer, 2019, 125(22), 3974-3984.
[http://dx.doi.org/10.1002/cncr.32392] [PMID: 31318460]
[29]
Yuan, Y.; Liu, X.; Cai, Y.; Li, W. Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review. PLoS One, 2023, 18(1), e0279775.
[http://dx.doi.org/10.1371/journal.pone.0279775] [PMID: 36602979]
[30]
Saura, C.; Oliveira, M.; Feng, Y.H.; Dai, M.S.; Chen, S.W.; Hurvitz, S.A.; Kim, S.B.; Moy, B.; Delaloge, S.; Gradishar, W.; Masuda, N.; Palacova, M.; Trudeau, M.E.; Mattson, J.; Yap, Y.S.; Hou, M.F.; De Laurentiis, M.; Yeh, Y.M.; Chang, H.T.; Yau, T.; Wildiers, H.; Haley, B.; Fagnani, D.; Lu, Y.S.; Crown, J.; Lin, J.; Takahashi, M.; Takano, T.; Yamaguchi, M.; Fujii, T.; Yao, B.; Bebchuk, J.; Keyvanjah, K.; Bryce, R.; Brufsky, A. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2- positive metastatic breast cancer previously treated with ≥ 2 HER2- directed regimens: Phase III NALA trial. J. Clin. Oncol., 2020, 38(27), 3138-3149.
[http://dx.doi.org/10.1200/JCO.20.00147] [PMID: 32678716]
[31]
Alasmari, M.M. A review of margetuximab-based therapies in patients with HER2-positive metastatic breast cancer. Cancers, 2022, 15(1), 38.
[http://dx.doi.org/10.3390/cancers15010038] [PMID: 36612034]
[32]
Rugo, H.S.; Im, S.A.; Cardoso, F.; Cortés, J.; Curigliano, G.; Musolino, A.; Pegram, M.D.; Wright, G.S.; Saura, C.; Escrivá-de-Romaní, S.; De Laurentiis, M.; Levy, C.; Brown-Glaberman, U.; Ferrero, J.M.; de Boer, M.; Kim, S.B.; Petráková, K.; Yardley, D.A.; Freedman, O.; Jakobsen, E.H.; Kaufman, B.; Yerushalmi, R.; Fasching, P.A.; Nordstrom, J.L.; Bonvini, E.; Koenig, S.; Edlich, S.; Hong, S.; Rock, E.P.; Gradishar, W.J. Efficacy of margetuximab vs. Trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial. JAMA Oncol., 2021, 7(4), 573-584.
[http://dx.doi.org/10.1001/jamaoncol.2020.7932] [PMID: 33480963]
[33]
Wynn, C.S.; Tang, S.C. Anti-HER2 therapy in metastatic breast cancer: Many choices and future directions. Cancer Metastasis Rev., 2022, 41(1), 193-209.
[http://dx.doi.org/10.1007/s10555-022-10021-x] [PMID: 35142964]
[34]
Piezzo, M.; D’Aniello, R.; Avallone, I.; Barba, B.; Cianniello, D.; Cocco, S.; D’Avino, A.; Di Gioia, G.; Di Lauro, V.; Fusco, G.; Piscitelli, R.; von Arx, C.; De Laurentiis, M.; Maiolino, P. Uptake of trastuzumab biosimilars for the treatment of HER2-positive breast cancer: A real-world experience from a cancer center. Pharmaceutics, 2021, 13(5), 684.
[http://dx.doi.org/10.3390/pharmaceutics13050684] [PMID: 34068626]
[35]
The selection and use of essential medicines: Report of the WHO expert committee on selection and use of essential medicines (Including the 21st WHO model list of essential medicines and the 7th WHO model list of essential medicines for children); License: CC BY-NC-SA 3.0 IGO, 2019. Available from: https://apps.who.int/iris/handle/10665/330668 (Accessed on 24 February 2023).
[36]
Rugo, H.S.; Linton, K.M.; Cervi, P.; Rosenberg, J.A.; Jacobs, I. A clinician’s guide to biosimilars in oncology. Cancer Treat. Rev., 2016, 46, 73-79.
[http://dx.doi.org/10.1016/j.ctrv.2016.04.003] [PMID: 27135548]
[37]
Greco, S.; Fabbri, N.; Spaggiari, R.; De Giorgi, A.; Fabbian, F.; Giovine, A. Update on classic and novel approaches in metastatic triple-negative breast cancer treatment: A comprehensive review. Biomedicines, 2023, 11(6), 1772.
[http://dx.doi.org/10.3390/biomedicines11061772] [PMID: 37371867]
[38]
Shi, M.; Li, Z.; Shen, G.; Wang, T.; Li, J.; Wang, M.; Liu, Z.; Zhao, F.; Ren, D.; Zhao, J. Efficacy and safety of first- line treatment for metastatic triple-negative breast cancer: A network meta-analysis. Cancer Pathogen. Ther., 2023.
[http://dx.doi.org/10.1016/j.cpt.2023.06.002]
[39]
Won, K.A.; Spruck, C. Triple-negative breast cancer therapy: Current and future perspectives (Review). Int. J. Oncol., 2020, 57(6), 1245-1261.
[http://dx.doi.org/10.3892/ijo.2020.5135] [PMID: 33174058]
[40]
Gerratana, L.; Fanotto, V.; Pelizzari, G.; Agostinetto, E.; Puglisi, F. Do platinum salts fit all triple negative breast cancers? Cancer Treat. Rev., 2016, 48, 34-41.
[http://dx.doi.org/10.1016/j.ctrv.2016.06.004] [PMID: 27343437]
[41]
Garutti, M.; Pelizzari, G.; Bartoletti, M.; Malfatti, M.C.; Gerratana, L.; Tell, G.; Puglisi, F. Platinum salts in patients with breast cancer: A focus on predictive factors. Int. J. Mol. Sci., 2019, 20(14), 3390.
[http://dx.doi.org/10.3390/ijms20143390] [PMID: 31295913]
[42]
Schmid, P.; Adams, S.; Rugo, H.S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Diéras, V.; Hegg, R.; Im, S.A.; Shaw Wright, G.; Henschel, V.; Molinero, L.; Chui, S.Y.; Funke, R.; Husain, A.; Winer, E.P.; Loi, S.; Emens, L.A. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med., 2018, 379(22), 2108-2121.
[http://dx.doi.org/10.1056/NEJMoa1809615] [PMID: 30345906]
[43]
Masuda, J.; Ozaki, Y.; Hara, F.; Kitano, S.; Takano, T. Pembrolizumab plus chemotherapy in triple-negative breast cancer. Lancet, 2021, 398(10294), 24.
[http://dx.doi.org/10.1016/S0140-6736(21)00380-9] [PMID: 34217392]
[44]
Carlino, F.; Diana, A.; Piccolo, A.; Ventriglia, A.; Bruno, V.; De Santo, I.; Letizia, O.; De Vita, F.; Daniele, B.; Ciardiello, F.; Orditura, M. Immune-based therapy in triple-negative breast cancer: From molecular biology to clinical practice. Cancers, 2022, 14(9), 2102.
[http://dx.doi.org/10.3390/cancers14092102] [PMID: 35565233]
[45]
Mavratzas, A.; Seitz, J.; Smetanay, K.; Schneeweiss, A.; Jäger, D.; Fremd, C. Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. Future Oncol., 2020, 16(3), 4439-4453.
[http://dx.doi.org/10.2217/fon-2019-0468] [PMID: 31829043]
[46]
Schmid, P.; Cortes, J.; Pusztai, L.; McArthur, H.; Kümmel, S.; Bergh, J.; Denkert, C.; Park, Y.H.; Hui, R.; Harbeck, N.; Takahashi, M.; Foukakis, T.; Fasching, P.A.; Cardoso, F.; Untch, M.; Jia, L.; Karantza, V.; Zhao, J.; Aktan, G.; Dent, R.; O’Shaughnessy, J. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med., 2020, 382(9), 810-821.
[http://dx.doi.org/10.1056/NEJMoa1910549] [PMID: 32101663]
[47]
Valenza, C.; Rizzo, G.; Passalacqua, M.I.; Boldrini, L.; Corti, C.; Trapani, D.; Curigliano, G. Evolving treatment landscape of immunotherapy in breast cancer: Current issues and future perspectives. Ther. Adv. Med. Oncol., 2023, 15
[http://dx.doi.org/10.1177/17588359221146129] [PMID: 36743524]
[48]
Capici, S.; Ammoni, L.C.; Meli, N.; Cogliati, V.; Pepe, F.F.; Piazza, F.; Cazzaniga, M.E. Personalised therapies for metastatic triple-negative breast cancer: When target is not everything. Cancers, 2022, 14(15), 3729.
[http://dx.doi.org/10.3390/cancers14153729] [PMID: 35954393]
[49]
Trapani, D.; Ferraro, E.; Giugliano, F.; Boscolo Bielo, L.; Curigliano, G.; Burstein, H.J. Postneoadjuvant treatment for triple-negative breast cancer. Curr. Opin. Oncol., 2022, 34(6), 623-634.
[http://dx.doi.org/10.1097/CCO.0000000000000893] [PMID: 35993306]
[50]
Catalano, A.; Iacopetta, D.; Ceramella, J.; Mariconda, A.; Rosano, C.; Scumaci, D.; Saturnino, C.; Longo, P.; Sinicropi, M. New achievements for the treatment of triple-negative breast cancer. Appl. Sci., 2022, 12(11), 5554.
[http://dx.doi.org/10.3390/app12115554]
[51]
Bravaccini, S.; Maltoni, R. Trop-2 therapy in metastatic triple-negative breast cancer in Italy: Clinical opportunity and regulatory pitfalls. J. Pers. Med., 2021, 11(11), 1211.
[http://dx.doi.org/10.3390/jpm11111211] [PMID: 34834563]
[52]
Cortesi, M.; Zanoni, M.; Maltoni, R.; Ravaioli, S.; Tumedei, M.M.; Pirini, F.; Bravaccini, S. TROP2 (trophoblast cell-surface antigen 2): A drug target for breast cancer. Expert Opin. Ther. Targets, 2022, 26(7), 593-602.
[http://dx.doi.org/10.1080/14728222.2022.2113513] [PMID: 35962580]
[53]
Miglietta, F.; Griguolo, G.; Bottosso, M.; Giarratano, T.; Lo Mele, M.; Fassan, M.; Cacciatore, M.; Genovesi, E.; De Bartolo, D.; Vernaci, G.; Amato, O.; Porra, F.; Conte, P.; Guarneri, V.; Dieci, M.V. HER2-low-positive breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatment. NPJ Breast Cancer, 2022, 8(1), 66.
[http://dx.doi.org/10.1038/s41523-022-00434-w] [PMID: 35595761]
[54]
Schlam, I.; Tolaney, S.M.; Tarantino, P. How I treat HER2-low advanced breast cancer. Breast, 2023, 67, 116-123.
[http://dx.doi.org/10.1016/j.breast.2023.01.005] [PMID: 36669993]
[55]
Modi, S.; Jacot, W.; Yamashita, T.; Sohn, J.; Vidal, M.; Tokunaga, E.; Tsurutani, J.; Ueno, N.T.; Prat, A.; Chae, Y.S.; Lee, K.S.; Niikura, N.; Park, Y.H.; Xu, B.; Wang, X.; Gil-Gil, M.; Li, W.; Pierga, J.Y.; Im, S.A.; Moore, H.C.F.; Rugo, H.S.; Yerushalmi, R.; Zagouri, F.; Gombos, A.; Kim, S.B.; Liu, Q.; Luo, T.; Saura, C.; Schmid, P.; Sun, T.; Gambhire, D.; Yung, L.; Wang, Y.; Singh, J.; Vitazka, P.; Meinhardt, G.; Harbeck, N.; Cameron, D.A. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med., 2022, 387(1), 9-20.
[http://dx.doi.org/10.1056/NEJMoa2203690] [PMID: 35665782]
[56]
Zhang, H.; Karakas, C.; Tyburski, H.; Turner, B.M.; Peng, Y.; Wang, X.; Katerji, H.; Schiffhauer, L.; Hicks, D.G. HER2-low breast cancers: Current insights and future directions. Semin. Diagn. Pathol., 2022, 39(5), 305-312.
[http://dx.doi.org/10.1053/j.semdp.2022.07.003] [PMID: 35872032]
[57]
FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-low-breast-cancer (Accessed on 27 February 2023).
[58]
Abuhelwa, Z.; Alloghbi, A.; Alqahtani, A.; Nagasaka, M. Trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies: A systematic review. Drugs, 2022, 82(9), 979-987.
[http://dx.doi.org/10.1007/s40265-022-01736-w] [PMID: 35759121]
[59]
Rugo, H.S.; Crossno, C.L.; Gesthalter, Y.B.; Kelley, K.; Moore, H.B.; Rimawi, M.F.; Westbrook, K.E.; Buys, S.S. Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2–expressing metastatic breast cancer. JCO Oncol. Pract., 2023, 19(8), 539-546.
[http://dx.doi.org/10.1200/OP.22.00480] [PMID: 37207306]
[60]
Soares, L.R.; Vilbert, M.; Rosa, V.D.L.; Oliveira, J.L.; Deus, M.M.; Freitas-Junior, R. Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: A systematic review and single-arm meta-analysis. ESMO Open, 2023, 8(4), 101613.
[http://dx.doi.org/10.1016/j.esmoop.2023.101613] [PMID: 37481956]
[61]
Crimini, E.; Tini, G.; Tarantino, P.; Ascione, L.; Repetto, M.; Beria, P.; Ranghiero, A.; Marra, A.; Belli, C.; Criscitiello, C.; Esposito, A.; Guerini Rocco, E.; Barberis, M.C.P.; Mazzarella, L.; Curigliano, G. Evaluation of the geographical accessibility of genome-matched clinical trials on a national experience. Oncologist, 2023, oyad229.
[http://dx.doi.org/10.1093/oncolo/oyad229] [PMID: 37669224]
[62]
Meattini, I.; Poortmans, P.M.P.; Marrazzo, L.; Desideri, I.; Brain, E.; Hamaker, M.; Lambertini, M.; Miccinesi, G.; Russell, N.; Saieva, C.; Strnad, V.; Visani, L.; Kaidar-Person, O.; Livi, L. Exclusive endocrine therapy or partial breast irradiation for women aged ≥70 years with luminal A-like early stage breast cancer (NCT04134598 – EUROPA): Proof of concept of a randomized controlled trial comparing health related quality of life by patient reported outcome measures. J. Geriatr. Oncol., 2021, 12(2), 182-189.
[http://dx.doi.org/10.1016/j.jgo.2020.07.013] [PMID: 32739355]
[63]
Botticelli, A.; Scagnoli, S.; Conte, P.; Cremolini, C.; Ascierto, P.A.; Cappuzzo, F.; Aglietta, M.; Mazzuca, F.; Capoluongo, E.; Blandino, G.; Malapelle, U.; Nuti, M.; D’Amati, G.; Cerbelli, B.; Pruneri, G.; Biffoni, M.; Giannini, G.; Cognetti, F.; Curigliano, G.; Marchetti, P. Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial. J. Clin. Oncol., 2022, 40(16_suppl)(Suppl.), 3087-3087.
[http://dx.doi.org/10.1200/JCO.2022.40.16_suppl.3087]
[64]
Gianni, L.; Pienkowski, T.; Im, Y.H.; Roman, L.; Tseng, L.M.; Liu, M.C.; Lluch, A.; Staroslawska, E.; de la Haba-Rodriguez, J.; Im, S.A.; Pedrini, J.L.; Poirier, B.; Morandi, P.; Semiglazov, V.; Srimuninnimit, V.; Bianchi, G.; Szado, T.; Ratnayake, J.; Ross, G.; Valagussa, P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2- positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol., 2012, 13(1), 25-32.
[http://dx.doi.org/10.1016/S1470-2045(11)70336-9] [PMID: 22153890]
[65]
Bianchini, G.; Kiermaier, A.; Bianchi, G.V.; Im, Y.H.; Pienkowski, T.; Liu, M.C.; Tseng, L.M.; Dowsett, M.; Zabaglo, L.; Kirk, S.; Szado, T.; Eng-Wong, J.; Amler, L.C.; Valagussa, P.; Gianni, L. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Res., 2017, 19(1), 16.
[http://dx.doi.org/10.1186/s13058-017-0806-9] [PMID: 28183321]
[66]
Lemieux, J.; Clemons, M.; Provencher, L.; Dent, S.; Latreille, J.; Mackey, J.; Pritchard, K.I.; Rayson, D.; Verma, S.; Verma, S.; Wang, B.; Chia, S. The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers. Curr. Oncol., 2009, 16(5), 48-57.
[http://dx.doi.org/10.3747/co.v16i5.510] [PMID: 19862361]
[67]
Swain, S.M.; Kim, S.B.; Cortés, J.; Ro, J.; Semiglazov, V.; Campone, M.; Ciruelos, E.; Ferrero, J.M.; Schneeweiss, A.; Knott, A.; Clark, E.; Ross, G.; Benyunes, M.C.; Baselga, J. Pertuzumab, trastuzumab, and docetaxel for HER2- positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol., 2013, 14(6), 461-471.
[http://dx.doi.org/10.1016/S1470-2045(13)70130-X] [PMID: 23602601]
[68]
Swain, S.M.; Miles, D.; Kim, S-B.; Im, Y.-H; Im, S.-A.; Semiglazov, V. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol., 2020, 21, 519-530.
[69]
Bachelot, T.; Ciruelos, E.; Schneeweiss, A.; Puglisi, F.; Peretz-Yablonski, T.; Bondarenko, I.; Paluch-Shimon, S.; Wardley, A.; Merot, J.L.; du Toit, Y.; Easton, V.; Lindegger, N.; Miles, D.; Bouzid, K.; Campone, M.; Coudert, B.; Nowecki, Z.; Errihani, H.; Dalenc, F.; Ferreira, A.; Mano, M.; Ricci, F.; Kalofonos, H.; Andreetta, C.; Montemurro, F.; Barrett, S.; Zhang, Q.; Mavroudis, D.; Matus, J.; Beato, C.; Hu, X.; Gaafar, R.; Abdel Azeem, H.; Perrin, C.; Ettl, J.; Lang, I.; Verma, S.; Li, H.; Brain, E.; Hoffmann, O.; Cariello, A.; Tondini, C.; Altwegeiri, T.; Loman, N.; Lux, M.; Frassoldati, A.; Aziz, Z.; Salas, F.; Streb, J.; Wronski, A.; Menjón Beltrán, S.; Cicin, I.; Schmid, P.; Laing, R.; Tong, Z.; Boer, K.; Juhasz, B.; Gianni, L.; Curigliano, G.; Juarez, A.; Susnjar, S.; Matos, E.; Uslu, R.; Wildiers, H.; Cruz, M.; Bourgeois, H.; von Schumann, R.; Stemmer, S.; Vásquez, F.M.; Dominguez, A.; Wojtukiewicz, M.; Trifunovic, J.; Illarramendi, J.J.; Garcia, L.; Peron, Y.I.; Echarri, M.J.; Voitko, N.; Wheatley, D.; Waters, S.; De Boer, R.; Jerusalem, G.; Cocquyt, V.; Barrios, C.; Panasci, L.; Mattson, J.; Tanner, M.; Gozy, M.; Vasilopoulos, G.; Revesz, J.; Latini, L.; Gridelli, C.; Lazaro, J.; Gonzalez, A.; Barnadas Molins, A.; Martinez, E.; Alarcón, J.; Arance, A.; Klint, L.; Kovalyov, O.; Baird, R.; Yeo, B.; McCarthy, N.; Greil, R.; Wang, S.; Artignan, X.; Augereau, P.; Juhasz-Boess, I.; Ngan, R.; Goldberg, H.; Di Costanzo, F.; Ferraù, F.; Aleknavicius, E.; Rashid, K.; Costa, L.; Angel Garcia, J.; de la Cruz, L.R.; López López, R.; Del Val, O.; Ozyilkan, O.; Azribi, F.; Verrill, M.; Turner, N.; Beith, J.; Petzer, A.; Andrade, J.; Bernstein, V.; Rayson, D.; Saad Eldin, I.; Achille, M.; Mueller, V.; Gennari, A.; Cascinu, S.; Ghosn, M.; El-Saghir, N.; Van den Bosch, J.; Oosterkamp, R.; Kukulska, M.; Pelaez, I.; Hernandez, C.; del Mar Gordon, M.; Dalmau, E.; Alonso, J.L.; Aksoy, S.; Coskun, H.S.; Shparyk, Y.; Varughese, M.; Panwar, U.; Barraclough, L.; Levitt, N.; Hicks, J.; Rigg, A.; Allen, M.; Castillo, C.; Fein, L.E.; Stuart-Harris, R.; Singer, C.; Stoeger, H.; Smiljanic, S.; Feng, J.; Cedeño, M.; Berdah, J.F.; Orfeuvre, H.; Goncalves, A.; Grischke, E-M.; Simon, E.; Wagner, S.; Efremidou, A.; Papazisis, K.; Evron, E.; Inbar, M.; Baruch, N.B.; Geffen, D.; Karminsky, N.; Ruggeri, E.M.; Luigi, C.; Grasso, D.; Juozaityte, E.; Rafael Rodriguez Cid, J.; Roerdink, H.; Siddiqi, N.; Passos Coelho, J.L.; Garre, E.G.; Garcia, A.; Martínez Jañez, N.; Lopez Ceballos, M.H.; Mele, M.; García, M.; Arcediano, A.; McAdam, K.; Perren, T.; Hicks, J.; Taylor, W.; Humphreys, A.; Vera, R.; Kaen, L.A.; Steger, G.; Andel, J.; de Grève, J.; Huizing, M.; Hegg, R.; Joy, A.; Sehdev, S.; Kütner, R.; Ruohola, J.; Dohollou, N.; Grosjean, J.; Laplaige, P.; Largillier, R.; Martin, P.; Pottier, V.; Alexandre, J.; Christensen, B.; Zahm, D-M.; Khandan, F.; Lueck, H-J.; Fountzilas, G.; Fried, G.; Giacobino, A.; Bonetti, A.; Guerra, Y.C.; Van Warmerdam, L.; Van der Velden, A.; Vrijaldenhoven, S.; de Jongh, F.; Cavero, M.; Andres Conejero, R.; Murias, A.; Saura, S.; Oltra, A.; Redondo, A.; Ribelles, N.; Bachmeier, K.; Joffe, J.; Chakraborti, P.; Beresford, M.; Butt, M.; Poole, C.; Yordi, G.; Woodward, N.; Amorim, G.; Califaretti, N.; Fox, S.; Robidoux, A.; Li, N.L.; Li, N.; Jiang, J.; Soria, T.; Padrik, P.; Saarni, O.; Genet, D.; Catala, S.; Barletta, H.; Teixeira, L.; Facchini, T.; Hesse, T.; Kühn, T.; Ober, A.; Repp, R.; Schroeder, W.; Pectasides, D.; Bodoky, G.; Kahan, Z.; Jiveliouk, I.; Rosengarten, O.; Alabiso, O.; Perez, M.; Van de Wouw, Y.; Smok-Kalwat, J.; Damasceno, M.; Sousa, G.; Abulkhair, O.; Antón Torres, A.; Martinez, M.P.; Garcia Mata, J.; Jesús Florián Jerico, M.S.; Llombart, A.; Sanchez, R.; Torrego, J.C.; Garate, C.O.; Rodriguez, C.; Llorente, R.; de Prado, D.S.; Cortés, J.; Llorca, C.; Galán, A.; Viñas Villaro, G.; Narbe, U.; Bjömeklett, H.G.; Westwell, S.; Newby, J.; Jafri, M.; Rodríguez, R.; Alonso, I. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann. Oncol., 2019, 30(5), 766-773.
[http://dx.doi.org/10.1093/annonc/mdz061] [PMID: 30796821]
[70]
Miles, D.; Ciruelos, E.; Schneeweiss, A.; Puglisi, F.; Peretz-Yablonski, T.; Campone, M.; Bondarenko, I.; Nowecki, Z.; Errihani, H.; Paluch-Shimon, S.; Wardley, A.; Merot, J.L.; Trask, P.; du Toit, Y.; Pena-Murillo, C.; Revelant, V.; Klingbiel, D.; Bachelot, T.; Bachelot, T.; Bouzid, K.; Campone, M.; Desmoulins, I.; Coudert, B.; Bondarenko, I.; Nowecki, Z.; Glogowska, I.; Ciruelos Gil, E.; Errihani, H.; Dalenc, F.; Ricci, F.; Dieras, V.; Kaufman, B.; Paluch-Shimon, S.; Wardley, A.; Schneeweiss, A.; Ferreira, A.; Mano, M.; Kalofonos, H.; Andreetta, C.; Puglisi, F.; Montemurro, F.; Barrett, S.; Zhang, Q.; Mavroudis, D.; Matus, J.; Villarreal Garza, C.; Beato, C.; Ismael, G.; Hu, X.; Abdel Azeem, H.; Gaafar, R.; Perrin, C.; Kerbrat, P.; Ettl, J.; Paepke, S.; Hitre, E.; Lang, I.; Trudeau, M.; Verma, S.; Li, H.; Hoffmann, O.; Aktas, B.; Cariello, A.; Cruciani, G.; Tienghi, A.; Tondini, C.; Al-Twegieri, T.; Loman, N.; Laing, R.; Miles, D.; Brain, E.; Fasching, P.; Lux, M.; Frassoldati, A.; Aziz, Z.; Salas, J.; Streb, J.; Krzemieniecki, K.; Wronski, A.; Garcia Garcia, J.; Menjon Beltran, S.; Cicin, I.; Schmid, P.; Gallagher, C.; Turner, N.; Tong, Z.; Boer, K.; Juhász, B.; Horvath, Z.; Bianchini, G.; Gianni, L.; Curigliano, G.; Juarez Ramiro, A.; Susnjar, S.; Matos, E.; Sevillano, E.; Garcia Estevez, L.; Gokmen, E.; Uslu, R.; Wildiers, H.; Schutz, F.; Cruz, M.; Bourgeois, H.; von Schumann, R.; Stemmer, S.; Dominguez, A.; Morales-Vásques, F.; Wojtukiewicz, M.; Trifunovic, J.; Echarri Gonzalez, M.J.; Illarramendi Mañas, J.; Martinez De Dueñas, E.; Voitko, N.; Hicks, J.; Waters, S.; Barrett-Lee, P.; Wheatley, D.; De Boer, R.; Cocquyt, V.; Jerusalem, G.; Barrios, C.; Panasci, L.; Mattson, J.; Tanner, M.; Gozy, M.; Vasilopoulos, G.; Papandreou, C.; Revesz, J.; Battelli, N.; Benedetti, G.; Latini, L.; Gridelli, C.; Lazaro Leon, J.; Alarcón Company, J.; Arance Fernandez, A.; Barnadas Molins, A.; Calvo Plaza, I.; Bratos, R.; Gonzalez Martin, A.; Izarzugaza Peron, Y.; Klint, L.; Kovalev, A.; McCarthy, N.; Yeo, B.; Kee, D.; Thomson, J.; White, S.; Greil, R.; Wang, S.; Artignan, X.; Juhasz-Böess, I.; Rody, A.; Ngan, R.; Dourleshter, F.; Goldberg, H.; Doni, L.; Di Costanzo, F.; Ferraù, F.; Drobniene, M.; Aleknavicius, E.; Rashid, K.; Costa, L.; de la Cruz Merino, L.; Garcia Saenz, J.; López, R.; Del Val Munoz, O.; Ozyilkan, O.; Azribi, F.; Jaafar, H.; Baird, R.; Verrill, M.; Beith, J.; Petzer, A.; Moreira de Andrade, J.; Bernstein, V.; Macpherson, N.; Rayson, D.; Saad Eldin, I.; Achille, M.; Augereau, P.; Müller, V.; Rasco, A.; Evron, E.; Katz, D.; Berardi, R.; Cascinu, S.; De Censi, A.; Gennari, A.; El-Saghir, N.; Ghosn, M.; Oosterkamp, H.M.; Van den Bosch, J.; Kukulska, M.; Kalinka, E.; Alonso, J.; Dalmau Portulas, E.; Del Mar Gordon Santiago, M.; Pelaez Fernandez, I.; Aksoy, S.; Altundag, K.; Senol Coskun, H.; Bozcuk, H.; Shparyk, Y.; Barraclough, L.; Hicks, J.; Levitt, N.; Panwar, U.; Kelly, S.; Rigg, A.; Varughese, M.; Castillo, C.; Fein, L.; Malik, L.; Stuart-Harris, R.; Singer, C.; Stoeger, H.; Samonigg, H.; Feng, J.; Cedeño, M.; Ruohola, J.; Berdah, J-F.; Goncalves, A.; Orfeuvre, H.; Grischke, E-M.; Simon, E.; Wagner, S.; Koumakis, G.; Papazisis, K.; Ben Baruch, N.; Fried, G.; Geffen, D.; Karminsky, N.; Peretz, T.; Cavanna, L.; Pedrazzioli, P.; Grasso, D.; Ruggeri, E.; D’Auria, G.; Moscetti, L.; Juozaityte, E.; Rodriguez Cid, J.; Roerdink, H.; Siddiqi, N.; Passos Coelho, J.; Arcediano Del Amo, A.; Garcia Garre, E.; García Gonzalez, M.; Garcia-Palomo Perez, A.; Herenandez Perez, C.; Lopez Alvarez, P.; Lopez De Ceballos, M.H.; Martínez Jañez, N.; Mele Olive, M.; McAdam, K.; Perren, T.; Dunn, G.; Humphreys, A.; Taylor, W.; Vera, R.; Kaen, L.; Andel, J.; Steger, G.; De Grève, J.; Huizing, M.; Hegg, R.; Joy, A.; Kuruvilla, P.; Sehdev, S.; Smiljanic, S.; Kütner, R.; Alexandre, J.; Grosjean, J.; Laplaige, P.; Largillier, R.; Maes, P.; Martin, P.; Pottier, V.; Christensen, B.; Khandan, F.; Lück, H-J.; Zahm, D-M.; Papandreou, C.; Fountzilas, G.; Karavasilis, V.; Safra, T.; Inbar, M.; Ryvo, L.; Bonetti, A.; Seles, E.; Giacobino, A.; Chavarri Guerra, Y.; de Jongh, F.; van der Velden, A.; van Warmerdam, L.; Vrijaldenhoven, S.; Smorenburg, C.H.; Cavero, M.; Andres Conejero, R.; Oltra Ferrando, A.; Redondo Sanchez, A.; Ribelles Entrena, N.; Saura Grau, S.; Viñas Vilaro, G.; Bachmeier, K.; Beresford, M.; Butt, M.; Joffe, J.; Poole, C.; Woodings, P.; Chakraborti, P.; Yordi, G.; Woodward, N.; Nobre, A.; Luiz Amorim, G.; Califaretti, N.; Fox, S.; Robidoux, A.; Li, E.; Li, N.; Jiang, J.; Soria, T.; Padrik, P.; Lahdenpera, O.; Barletta, H.; Dohollou, N.; Genet, D.; Prulhiere, K.; Coeffic, D.; Facchini, T.; Vieillot, S.; Catala, S.; Teixeira, L.; Hesse, T.; Kühn, T.; Ober, A.; Repp, R.; Schröder, W.; Pectasides, D.; Bodoky, G.; Kahan, Z.; Jiveliouk, I.; Rosengarten, O.; Rossi, V.; Alabiso, O.; Pérez Martínez, M.; van de Wouw, A.J.; Smok-Kalwat, J.; Damasecno, M.; Augusto, I.; Sousa, G.; Saadein, A.; Abdelhafiez, N.; Abulkhair, O.; Antón Torres, A.; Corbellas Aparicio, M.; Llorente Domenech, R.; Florián Jerico, J.; Garcia Mata, J.; Gil Raga, M.; Galan Brotons, A.; Llombart Cussac, A.; Llorca Ferrandiz, C.; Martinez Del Prado, P.; Olier Garate, C.; Rodriguez Sanchez, C.; Sanchez Gomez, R.; Santisteban Eslava, M.; Soberino, J.; Vidal Losada Garcia, M.; Soto de Prado, D.; Torrego Garcia, J.; Vicente Rubio, E.; Garcia, M.; Murias Rosales, A.; Granstam Björneklett, H.; Narbe, U.; Jafri, M.; Rea, D.; Newby, J.; Jones, A.; Westwell, S.; Ring, A.; Alonso, I.; Rodríguez, R. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann. Oncol., 2021, 32(10), 1245-1255.
[http://dx.doi.org/10.1016/j.annonc.2021.06.024] [PMID: 34224826]
[71]
Schneeweiss, A.; Chia, S.; Hickish, T.; Harvey, V.; Eniu, A.; Waldron-Lynch, M.; Eng-Wong, J.; Kirk, S.; Cortés, J. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur. J. Cancer, 2018, 89, 27-35.
[http://dx.doi.org/10.1016/j.ejca.2017.10.021] [PMID: 29223479]
[72]
Squires, H.; Pandor, A.; Thokala, P.; Stevens, J.W.; Kaltenthaler, E.; Clowes, M.; Coleman, R.; Wyld, L. Pertuzumab for the neoadjuvant treatment of early-stage HER2-positive breast cancer: An evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics, 2018, 36(1), 29-38.
[http://dx.doi.org/10.1007/s40273-017-0556-7] [PMID: 28770452]
[73]
Piccart, M.; Procter, M.; Fumagalli, D.; De Azambuja, E.; Clark, E.; Ewer, M.S. Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable her2-positive early breast cancer. Gen. Sess. Abstr., 2020, 80, GS1-GS04.
[74]
Bines, J.; Clark, E.; Barton, C.; Restuccia, E.; Procter, M.; Sonnenblick, A.; Fumagalli, D.; Parlier, D.; Arahmani, A.; Baselga, J.; Viale, G.; Reaby, L.L.; Frank, E.; Gelber, R.D.; Piccart, M.; Jackisch, C.; Petersen, J.A. Patient-reported function, health-related quality of life, and symptoms in APHINITY: Pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. Br. J. Cancer, 2021, 125(1), 38-47.
[http://dx.doi.org/10.1038/s41416-021-01323-y] [PMID: 33828257]
[75]
de Azambuja, E.; Agostinetto, E.; Procter, M.; Eiger, D.; Pondé, N.; Guillaume, S.; Parlier, D.; Lambertini, M.; Desmet, A.; Caballero, C.; Aguila, C.; Jerusalem, G.; Walshe, J.M.; Frank, E.; Bines, J.; Loibl, S.; Piccart-Gebhart, M.; Ewer, M.S.; Dent, S.; Plummer, C.; Suter, T. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO Open, 2023, 8(1), 100772.
[http://dx.doi.org/10.1016/j.esmoop.2022.100772] [PMID: 36681013]
[76]
Rimawi, M.; Ferrero, J.M.; de la Haba-Rodriguez, J.; Poole, C.; De Placido, S.; Osborne, C.K.; Hegg, R.; Easton, V.; Wohlfarth, C.; Arpino, G. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2–positive and hormone receptor–positive metastatic or locally advanced breast cancer (PERTAIN): A randomized, open-label phase II trial. J. Clin. Oncol., 2018, 36(28), 2826-2835.
[http://dx.doi.org/10.1200/JCO.2017.76.7863] [PMID: 30106636]
[77]
Bartsch, R. SABCS 2020: Update on triple-negative and metastatic HER2-positive breast cancer. Mag. Eur. Med. Oncol., 2021, 14(3), 247-251.
[http://dx.doi.org/10.1007/s12254-021-00722-4] [PMID: 34221179]
[78]
Arpino, G.; de la Haba-Rodriguez, J.; Ferrero, J.M.; De Placido, S.; Klingbiel, D.; Revelant, V.; Wohlfarth, C.; Poppe, R.; Rimawi, M.F. Abstract PD3-02: Final analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of first-line pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer. Cancer Res., 2021, 81(4_Supplement)(Suppl.), PD3-02.
[http://dx.doi.org/10.1158/1538-7445.SABCS20-PD3-02]
[79]
Wildiers, H.; Tryfonidis, K.; Dal Lago, L.; Vuylsteke, P.; Curigliano, G.; Waters, S.; Brouwers, B.; Altintas, S.; Touati, N.; Cardoso, F.; Brain, E. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): An open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol., 2018, 19(3), 323-336.
[http://dx.doi.org/10.1016/S1470-2045(18)30083-4] [PMID: 29433963]
[80]
Wildiers, H.; Meyskens, T.; Marréaud, S.; Lago, L.D.; Vuylsteke, P.; Curigliano, G.; Waters, S.; Brouwers, B.; Meulemans, B.; Sousa, B.; Poncet, C.; Brain, E. Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. Breast, 2022, 64, 100-111.
[http://dx.doi.org/10.1016/j.breast.2022.05.004] [PMID: 35636341]
[81]
Wildiers, H.; Marreaud, S.; Lago, L.D.; Vuylsteke, P.; Curigliano, G.; Waters, S.; Brouwers, B.; Meulemans, B.; Sousa, B.; Poncet, C.; Brain, E. Abstract P1-18-06: Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer, followed by T-DM1 after progression. Cancer Res., 2022, 82(4_Supplement)(Suppl.), P1-18-06.
[http://dx.doi.org/10.1158/1538-7445.SABCS21-P1-18-06]
[82]
Hurvitz, S.A.; Martin, M.; Symmans, W.F.; Jung, K.H.; Huang, C.S.; Thompson, A.M.; Harbeck, N.; Valero, V.; Stroyakovskiy, D.; Wildiers, H.; Campone, M.; Boileau, J.F.; Beckmann, M.W.; Afenjar, K.; Fresco, R.; Helms, H.J.; Xu, J.; Lin, Y.G.; Sparano, J.; Slamon, D. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): A randomised, open-label, multicentre, phase 3 trial. Lancet Oncol., 2018, 19(1), 115-126.
[http://dx.doi.org/10.1016/S1470-2045(17)30716-7] [PMID: 29175149]
[83]
de Haas, S.L.; Slamon, D.J.; Martin, M.; Press, M.F.; Lewis, G.D.; Lambertini, C.; Prat, A.; Lopez-Valverde, V.; Boulet, T.; Hurvitz, S.A. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: An open-label, phase III study (KRISTINE). Breast Cancer Res., 2023, 25(1), 2.
[http://dx.doi.org/10.1186/s13058-022-01587-z] [PMID: 36631725]
[84]
Tolaney, S.M.; Tayob, N.; Dang, C.; Yardley, D.A.; Isakoff, S.J.; Valero, V.; Faggen, M.; Mulvey, T.; Bose, R.; Hu, J.; Weckstein, D.; Wolff, A.C.; Reeder-Hayes, K.; Rugo, H.S.; Ramaswamy, B.; Zuckerman, D.; Hart, L.; Gadi, V.K.; Constantine, M.; Cheng, K.; Briccetti, F.; Schneider, B.; Garrett, A.M.; Marcom, K.; Albain, K.; DeFusco, P.; Tung, N.; Ardman, B.; Nanda, R.; Jankowitz, R.C.; Rimawi, M.; Abramson, V.; Pohlmann, P.R.; Van Poznak, C.; Forero-Torres, A.; Liu, M.; Ruddy, K.; Zheng, Y.; Rosenberg, S.M.; Gelber, R.D.; Trippa, L.; Barry, W.; DeMeo, M.; Burstein, H.; Partridge, A.; Winer, E.P.; Krop, I. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): A randomized clinical trial. J. Clin. Oncol., 2021, 39(21), 2375-2385.
[http://dx.doi.org/10.1200/JCO.20.03398] [PMID: 34077270]
[85]
Bellon, J.R.; Tayob, N.; Yang, D.D.; Tralins, J.; Dang, C.T.; Isakoff, S.J.; DeMeo, M.; Burstein, H.J.; Partridge, A.H.; Winer, E.P.; Krop, I.E.; Tolaney, S.M. Local therapy outcomes and toxicity from the ATEMPT Trial (TBCRC 033): A phase II randomized trial of adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer. Int. J. Radiat. Oncol. Biol. Phys., 2022, 113(1), 117-124.
[http://dx.doi.org/10.1016/j.ijrobp.2021.12.173] [PMID: 34990776]
[86]
Barroso-Sousa, R.; Tarantino, P.; Tayob, N.; Dang, C.; Yardley, D.A.; Isakoff, S.J.; Valero, V.; Faggen, M.; Mulvey, T.; Bose, R.; Hu, J.; Weckstein, D.; Wolff, A.C.; Reeder-Hayes, K.; Rugo, H.S.; Ramaswamy, B.; Zuckerman, D.; Hart, L.; Gadi, V.K.; Constantine, M.; Cheng, K.; Briccetti, F.; Schneider, B.; Garrett, A.M.; Marcom, K.; Albain, K.; DeFusco, P.; Tung, N.; Ardman, B.; Nanda, R.; Jankowitz, R.C.; Rimawi, M.; Abramson, V.; Pohlmann, P.R.; Van Poznak, C.; Forero-Torres, A.; Liu, M.; Ruddy, K.J.; Zheng, Y.; Rosenberg, S.M.; Gelber, R.D.; Trippa, L.; Barry, W.; DeMeo, M.; Burstein, H.; Partridge, A.; Winer, E.P.; Krop, I.; Tolaney, S.M. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): A randomized controlled trial. NPJ Breast Cancer, 2022, 8(1), 18.
[http://dx.doi.org/10.1038/s41523-022-00385-2] [PMID: 35173164]
[87]
Curigliano, G.; Mueller, V.; Borges, V.; Hamilton, E.; Hurvitz, S.; Loi, S.; Murthy, R.; Okines, A.; Paplomata, E.; Cameron, D.; Carey, L.A.; Gelmon, K.; Hortobagyi, G.N.; Krop, I.; Loibl, S.; Pegram, M.; Slamon, D.; Ramos, J.; Feng, W.; Winer, E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann. Oncol., 2022, 33(3), 321-329.
[http://dx.doi.org/10.1016/j.annonc.2021.12.005] [PMID: 34954044]
[88]
Modi, S.; Saura, C.; Yamashita, T.; Park, Y.H.; Kim, S.B.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; Sohn, J.; Denduluri, N.; Perrin, C.; Aogi, K.; Tokunaga, E.; Im, S.A.; Lee, K.S.; Hurvitz, S.A.; Cortes, J.; Lee, C.; Chen, S.; Zhang, L.; Shahidi, J.; Yver, A.; Krop, I. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med., 2020, 382(7), 610-621.
[http://dx.doi.org/10.1056/NEJMoa1914510] [PMID: 31825192]
[89]
Markham, A. Margetuximab: First approval. Drugs, 2021, 81(5), 599-604.
[http://dx.doi.org/10.1007/s40265-021-01485-2] [PMID: 33761116]
[90]
MARGetuximab Or Trastuzumab (MARGOT) (MARGOT). 2023. Available from: https://beta.clinicaltrials.gov/study/NCT04425018?tab=results (Accessed on 10 April 2023).
[91]
Dang, C.; Ewer, M.S.; Delaloge, S.; Ferrero, J.M.; Colomer, R.; de la Cruz-Merino, L.; Werner, T.L.; Dadswell, K.; Verrill, M.; Eiger, D.; Sarkar, S.; de Haas, S.L.; Restuccia, E.; Swain, S.M. BERENICE final analysis: Cardiac safety study of neoadjuvant pertuzumab, trastuzumab, and chemotherapy followed by adjuvant pertuzumab and trastuzumab in HER2-positive early breast cancer. Cancers, 2022, 14(11), 2596.
[http://dx.doi.org/10.3390/cancers14112596] [PMID: 35681574]
[92]
Miglietta, F.; Pronzato, P.; Girardi, F.; Griguolo, G.; Guarneri, V.; Pappagallo, G.; Conte, P. Residual risk of relapse: a systematic review and a consensus project on unmet needs for HER2-positive non metastatic breast cancer patients. Eur. J. Cancer, 2022, 175, S57-S58.
[http://dx.doi.org/10.1016/S0959-8049(22)01504-0]
[93]
Gluz, O.; Nitz, U.; Liedtke, C.; Christgen, M.; Grischke, E.M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Lindner, C.; Kuemmel, S.; Clemens, M.; Potenberg, J.; Staib, P.; Kohls, A.; von Schumann, R.; Kates, R.; Kates, R.; Schumacher, J.; Wuerstlein, R.; Kreipe, H.H.; Harbeck, N. Comparison of neoadjuvant Nab-Paclitaxel + Carboplatin vs Nab-Paclitaxel + Gemcitabine in triple-negative breast cancer: Randomized WSG-ADAPT-TN trial results. J. Natl. Cancer Inst., 2018, 110(6), 628-637.
[http://dx.doi.org/10.1093/jnci/djx258] [PMID: 29228315]
[94]
Kolberg-Liedtke, C.; Feuerhake, F.; Garke, M.; Christgen, M.; Kates, R.; Grischke, E.M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Kuemmel, S.; Wuerstlein, R.; Graeser, M.; Nitz, U.; Kreipe, H.; Gluz, O.; Harbeck, N. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial. Breast Cancer Res., 2022, 24(1), 58.
[http://dx.doi.org/10.1186/s13058-022-01552-w] [PMID: 36056374]
[95]
Bardia, A.; Hurvitz, S.A.; Tolaney, S.M.; Loirat, D.; Punie, K.; Oliveira, M.; Brufsky, A.; Sardesai, S.D.; Kalinsky, K.; Zelnak, A.B.; Weaver, R.; Traina, T.; Dalenc, F.; Aftimos, P.; Lynce, F.; Diab, S.; Cortés, J.; O’Shaughnessy, J.; Diéras, V.; Ferrario, C.; Schmid, P.; Carey, L.A.; Gianni, L.; Piccart, M.J.; Loibl, S.; Goldenberg, D.M.; Hong, Q.; Olivo, M.S.; Itri, L.M.; Rugo, H.S. ASCENT clinical trial investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med., 2021, 384(16), 1529-1541.
[http://dx.doi.org/10.1056/NEJMoa2028485] [PMID: 33882206]
[96]
Cejuela, M.; Vethencourt, A.; Pernas, S. Immune checkpoint inhibitors and novel immunotherapy approaches for breast cancer. Curr. Oncol. Rep., 2022, 24(12), 1801-1819.
[http://dx.doi.org/10.1007/s11912-022-01339-4] [PMID: 36255603]
[97]
Nicolò, E.; Tarantino, P.; Curigliano, G. Biology and treatment of HER2-low breast cancer. Hematol. Oncol. Clin. North Am., 2023, 37(1), 117-132.
[http://dx.doi.org/10.1016/j.hoc.2022.08.013] [PMID: 36435605]
[98]
Fehrenbacher, L.; Cecchini, R.S.; Geyer, C.E., Jr; Rastogi, P.; Costantino, J.P.; Atkins, J.N.; Crown, J.P.; Polikoff, J.; Boileau, J.F.; Provencher, L.; Stokoe, C.; Moore, T.D.; Robidoux, A.; Flynn, P.J.; Borges, V.F.; Albain, K.S.; Swain, S.M.; Paik, S.; Mamounas, E.P.; Wolmark, N. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+. J. Clin. Oncol., 2020, 38(5), 444-453.
[http://dx.doi.org/10.1200/JCO.19.01455] [PMID: 31821109]
[99]
Carlino, F.; Diana, A.; Ventriglia, A.; Piccolo, A.; Mocerino, C.; Riccardi, F.; Bilancia, D.; Giotta, F.; Antoniol, G.; Famiglietti, V.; Feliciano, S.; Cangiano, R.; Lobianco, L.; Pellegrino, B.; De Vita, F.; Ciardiello, F.; Orditura, M. HER2-low status does not affect survival outcomes of patients with metastatic breast cancer (MBC) undergoing first-line treatment with endocrine therapy plus palbociclib: Results of a multicenter, retrospective cohort study. Cancers, 2022, 14(20), 4981.
[http://dx.doi.org/10.3390/cancers14204981] [PMID: 36291765]
[100]
AstraZeneca. A phase 3, randomized, multi-center, open-label study of trastuzumab deruxtecan (T-DXd) versus investigator’s choice chemotherapy in HER2-low, hormone receptor positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting (DESTINY-Breast06). Available from: https://clinicaltrials.gov/ct2/show/NCT04494425 (Accessed on 27 February 2023)
[101]
Gombos, A.; Goncalves, A.; Curigliano, G.; Bartsch, R.; Kyte, J.A.; Ignatiadis, M.; Awada, A. How I treat endocrine-dependent metastatic breast cancer. ESMO Open, 2023, 8(2), 100882.
[http://dx.doi.org/10.1016/j.esmoop.2023.100882] [PMID: 36806375]
[102]
Singh, B.; Olds, T.; Curtis, R.; Dumuid, D.; Virgara, R.; Watson, A.; Szeto, K.; O’Connor, E.; Ferguson, T.; Eglitis, E.; Miatke, A.; Simpson, C.E.M.; Maher, C. Effectiveness of physical activity interventions for improving depression, anxiety and distress: An overview of systematic reviews. Br. J. Sports Med., 2023, 57(18), 1203-1209.
[http://dx.doi.org/10.1136/bjsports-2022-106195] [PMID: 36796860]
[103]
Cowan, S.; Lim, S.; Alycia, C.; Pirotta, S.; Thomson, R.; Gibson-Helm, M.; Blackmore, R.; Naderpoor, N.; Bennett, C.; Ee, C.; Rao, V.; Mousa, A.; Alesi, S.; Moran, L. Lifestyle management in polycystic ovary syndrome – beyond diet and physical activity. BMC Endocr. Disord., 2023, 23(1), 14.
[http://dx.doi.org/10.1186/s12902-022-01208-y] [PMID: 36647089]
[104]
Catalano, A. COVID-19: Could irisin become the handyman myokine of the 21st century? Coronaviruses, 2020, 1(1), 32-41.
[http://dx.doi.org/10.2174/2666796701999200617154655]
[105]
Li, C.; Shang, S.; Liang, W. Physical activity types, physical activity levels and risk of diabetes in general adults: The NHANES 2007–2018. Int. J. Environ. Res. Public Health, 2023, 20(2), 1398.
[http://dx.doi.org/10.3390/ijerph20021398] [PMID: 36674154]
[106]
Fresno-Alba, S.; Denche-Zamorano, Á.; Pastor-Cisneros, R.; Pereira-Payo, D.; Franco-García, J.M.; Jiménez- Castuera, R. Breast cancer and physical activity: A bibliometric analysis. Front. Oncol., 2023, 12, 1051482.
[http://dx.doi.org/10.3389/fonc.2022.1051482] [PMID: 36713550]
[107]
Spei, M.E.; Samoli, E.; Bravi, F.; La Vecchia, C.; Bamia, C.; Benetou, V. Physical activity in breast cancer survivors: A systematic review and meta-analysis on overall and breast cancer survival. Breast, 2019, 44, 144-152.
[http://dx.doi.org/10.1016/j.breast.2019.02.001] [PMID: 30780085]
[108]
Swain, C.T.V.; Drummond, A.E.; Boing, L.; Milne, R.L.; English, D.R.; Brown, K.A.; van Roekel, E.H.; Dixon- Suen, S.C.; Lynch, M.J.; Moore, M.M.; Gaunt, T.R.; Martin, R.M.; Lewis, S.J.; Lynch, B.M. Linking physical activity to breast cancer via sex hormones, part 1: The effect of physical activity on sex steroid hormones. Cancer Epidemiol. Biomarkers Prev., 2022, 31(1), 16-27.
[http://dx.doi.org/10.1158/1055-9965.EPI-21-0437] [PMID: 34670800]
[109]
De Placido, S.; Giuliano, M.; Schettini, F.; Von Arx, C.; Buono, G.; Riccardi, F.; Cianniello, D.; Caputo, R.; Puglisi, F.; Bonotto, M.; Fabi, A.; Bilancia, D.; Ciccarese, M.; Lorusso, V.; Michelotti, A.; Bruzzese, D.; Veneziani, B.M.; Locci, M.; De Laurentiis, M.; Arpino, G. Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. Breast, 2018, 38, 86-91.
[http://dx.doi.org/10.1016/j.breast.2017.12.012] [PMID: 29287189]
[110]
Perez, E.A.; López-Vega, J.M.; Petit, T.; Zamagni, C.; Easton, V.; Kamber, J.; Restuccia, E.; Andersson, M. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res., 2016, 18(1), 126.
[http://dx.doi.org/10.1186/s13058-016-0773-6] [PMID: 27955684]
[111]
Alam, M.M.; Rahman, T.; Afroz, Z.; Chakraborty, P.A.; Wahab, A.; Zaman, S.; Hawlader, M.D.H. Quality of Life (QoL) of cancer patients and its association with nutritional and performance status: A pilot study. Heliyon, 2020, 6(10), e05250.
[http://dx.doi.org/10.1016/j.heliyon.2020.e05250] [PMID: 33134577]
[112]
Sprangers, M.A.; Groenvold, M.; Arraras, J.I.; Franklin, J.; te Velde, A.; Muller, M.; Franzini, L.; Williams, A.; de Haes, H.C.; Hopwood, P.; Cull, A.; Aaronson, N.K. The european organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. J. Clin. Oncol., 1996, 14(10), 2756-2768.
[http://dx.doi.org/10.1200/JCO.1996.14.10.2756] [PMID: 8874337]
[113]
Giesinger, J.M.; Loth, F.L.C.; Aaronson, N.K.; Arraras, J.I.; Caocci, G.; Efficace, F.; Groenvold, M.; van Leeuwen, M.; Petersen, M.A.; Ramage, J.; Tomaszewski, K.A.; Young, T.; Holzner, B. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J. Clin. Epidemiol., 2020, 118, 1-8.
[http://dx.doi.org/10.1016/j.jclinepi.2019.10.003] [PMID: 31639445]
[114]
Iacopetta, D.; Ceramella, J.; Catalano, A.; Saturnino, C.; Pellegrino, M.; Mariconda, A.; Longo, P.; Sinicropi, M.S.; Aquaro, S. COVID-19 at a glance: An up-to-date overview on variants, drug design and therapies. Viruses, 2022, 14(3), 573.
[http://dx.doi.org/10.3390/v14030573] [PMID: 35336980]
[115]
Bjelic-Radisic, V.; Cardoso, F.; Cameron, D.; Brain, E.; Kuljanic, K.; da Costa, R.A.; Conroy, T.; Inwald, E.C.; Serpentini, S.; Pinto, M.; Weis, J.; Morag, O.; Lindviksmoen Astrup, G.; Tomaszweksi, K.A.; Pogoda, K.; Sinai, P.; Sprangers, M.; Aaronson, N.; Velikova, G.; Greimel, E.; Arraras, J.; Bottomley, A.; Bleiker, E.; Bliem, B.; Chie, W.; Creutzberg, C.; Deville, V.; Duhoux, F.; Eilf, K.; Hartup, S.; Koller, M.; Nagele, E.; Nicolatou-Galitis, O.; Oberguggenberger, A.; Schmalz, C.; Winters, Z. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. Ann. Oncol., 2020, 31(2), 283-288.
[http://dx.doi.org/10.1016/j.annonc.2019.10.027] [PMID: 31959345]
[116]
Chiesi, F.; Vizza, D.; Valente, M.; Bruno, R.; Lau, C.; Campagna, M.R.; Lo Iacono, M.; Bruno, F. Positive personal resources and psychological distress during the COVID-19 pandemic: Resilience, optimism, hope, courage, trait mindfulness, and self-efficacy in breast cancer patients and survivors. Support. Care Cancer, 2022, 30(8), 7005-7014.
[http://dx.doi.org/10.1007/s00520-022-07123-1] [PMID: 35579755]
[117]
Adams-Campbell, L.L.; Hicks, J.; Makambi, K.; Randolph-Jackson, P.; Mills, M.; Isaacs, C.; Dash, C. An 8-week exercise study to improve cancer treatment related fatigue and QOL among African American breast cancer patients undergoing radiation treatment: A pilot randomized clinical trial. J. Natl. Med. Assoc., 2023, 115(2), 199-206.
[http://dx.doi.org/10.1016/j.jnma.2023.01.011] [PMID: 36828705]
[118]
Cariolou, M.; Abar, L.; Aune, D.; Balducci, K.; Becerra- Tomás, N.; Greenwood, D.C.; Markozannes, G.; Nanu, N.; Vieira, R.; Giovannucci, E.L.; Gunter, M.J.; Jackson, A.A.; Kampman, E.; Lund, V.; Allen, K.; Brockton, N.T.; Croker, H.; Katsikioti, D.; McGinley-Gieser, D.; Mitrou, P.; Wiseman, M.; Cross, A.J.; Riboli, E.; Clinton, S.K.; McTiernan, A.; Norat, T.; Tsilidis, K.K.; Chan, D.S.M. Postdiagnosis recreational physical activity and breast cancer prognosis: Global cancer update programme (CUP global) systematic literature review and meta-analysis. Int. J. Cancer, 2023, 152(4), 600-615.
[http://dx.doi.org/10.1002/ijc.34324] [PMID: 36279903]
[119]
Murri, A.; Vitucci, D.; Tranchita, E.; Grazioli, E.; Gori, S.; Modena, A.; Turazza, M.; Filippini, R.; Galeazzi, S.; Verzè, M.; Frittelli, P.; Corsi, D.C.; Nicolis, F.; Parisi, A.; Cerulli, C. “OPERATION PHALCO” Adapted physical activity for breast cancer survivors: Is it time for a multidisciplinary approach? Cancers, 2022, 15(1), 34.
[http://dx.doi.org/10.3390/cancers15010034] [PMID: 36612031]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy